Hutchmed Says Supplemental New Drug Application for Savolitinib Accepted for Review in China
Hutchmed Says Supplemental New Drug Application for Savolitinib Accepted for Review in China
和黃醫藥稱沃利替尼的補充新藥申請在中國受理審查
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊